Sec. 101. Development of best prescribing practices
432 words·~2 min read·
/bill/114/s/524/rs/section-101A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Not later than 120 days after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the Secretary ), in cooperation with the Secretary of Veterans Affairs, the Secretary of Defense, and the Administrator of the Drug Enforcement Administration, shall convene a Pain Management Best Practices Inter-Agency Task Force (referred to in this section as the task force ). The task force shall be comprised of— representatives of— the Department of Health and Human Services; the Department of Veterans Affairs; the Department of Defense; the Drug Enforcement Administration; the Centers for Disease Control and Prevention; the Institute of Medicine; and the Office of National Drug Control Policy; the Director of the National Institutes of Health; physicians, dentists, and non-physician prescribers; pharmacists; experts in the fields of pain research and addiction research; representatives of— pain management professional organizations; the mental health treatment community; the addiction treatment community; pain advocacy groups; and groups with expertise around overdose reversal; and other stakeholders, as the Secretary determines appropriate.
The task force shall— not later than 180 days after the date on which the task force is convened under subsection (a), develop best practices for pain management (including chronic and acute pain) and prescribing pain medication, taking into consideration— existing pain management research; recommendations from relevant conferences; ongoing efforts at the State and local levels and by medical professional organizations to develop improved pain management strategies; and the management of high-risk populations, other than populations who suffer pain, who— may use or be prescribed benzodiazepines, alcohol, and diverted opioids; or receive opioids in the course of medical care; solicit and take into consideration public comment on the practices developed under paragraph (1), amending such best practices if appropriate; and develop a strategy for disseminating information about the best practices developed under paragraphs
(1)and
(2)to prescribers, health professionals, pharmacists, State medical boards, and other parties, as the Secretary determines appropriate. The task force shall not have rulemaking authority. Not later than 270 days after the date on which the task force is convened under subsection (a), the task force shall submit to Congress a report that includes— the strategy for disseminating best practices developed under subsection (c); the results of a feasibility study on linking best practices developed under subsection
(c)to receiving and renewing registrations under section 303(f) of the Controlled Substances Act ( 21 U.S.C. 823(f) ); and recommendations on how to apply best practices developed under subsection
(c)to improve prescribing practices at medical facilities, including medical facilities of the Veterans Health Administration.
Connectionstraces to 1
Traces to 1 document
U.S. Code
Citation graph
cites case law
Sec. 101
Development of best prescribing practices
Cites 1Cited by 0 across 0 sources